Data from meta-analysis ([Non-small Cell Lung Cancer Collaborative Group, 1995](#bib12){ref-type="other"}) show a slight but significant median survival advantage (6 weeks) for platinum-containing chemotherapy in the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Some benefit was also shown for chemotherapy in elderly patients, in terms of both survival and quality of life ([The ELVIS group, 1999](#bib16){ref-type="other"}).

Based on these results, although the efficacy of currently available chemotherapy is far from being satisfactory, the majority of patients diagnosed with advanced NSCLC are offered chemotherapy. In addition to antineoplastic drugs, a variable number of different drugs are given as supportive care (SC), that is, '*every treatment given to prevent, control or relieve complications and side effects and to improve the patient\'s comfort and quality of life of people who have cancer*' ([National Cancer Institute Dictionary, 2002](#bib11){ref-type="other"}).

The concomitant assumption of several drugs leads to obvious pharmacoeconomic and practical problems of compliance for patients, and raises important safety issues. Pharmacological interactions are identified as one of the eight 'drug-related problems' ([Strand *et al*, 1990](#bib15){ref-type="other"}) and are a common and serious consequence of polypharmacotherapy ([Cadieux, 1989](#bib5){ref-type="other"}). At a pharmacokinetic level, one drug can interfere with absorption, distribution, metabolism and excretion of another drug. Moreover, the assumption of a high number of drugs can reduce patients\' compliance and, more dangerously, induce errors of dose and timing of assumption ([Hulka *et al*, 1975](#bib8){ref-type="other"}). All of these problems can give rise to toxic effects, especially when drugs with a low therapeutic index, like cytotoxic drugs, are used.

The present study has two main aims: first, to give a picture of the number and variety of supportive drugs assumed by patients with advanced NSCLC during chemotherapy, and, second, to assess the impact of chemotherapy, patient\'s performance status (PS) and patient\'s age on the assumption of SC.

MATERIALS AND METHODS
=====================

Patients
--------

Patients with advanced NSCLC who participated in three randomised clinical trials ([The ELVIS group, 1999](#bib16){ref-type="other"}; [Gridelli *et al*, 2003a](#bib6){ref-type="other"}, [2003b](#bib7){ref-type="other"}) performed by our cooperative group between 1996 and 2001 were selected for this study. All three studies were approved by Ethical Committees, and all patients gave written informed consent. They had stage IV or IIIB (with supraclavicular metastatic nodes or malignant pleural effusion) disease and a baseline PS not worse than 2, according to the ECOG scale ([Oken *et al*, 1982](#bib13){ref-type="other"}).

In the ELVIS study (Elderly) Lung cancer Vinorelbine Italian Study ([The ELVIS group, 1999](#bib16){ref-type="other"}), vinorelbine was compared with SC alone in patients ⩾70 years. Vinorelbine was given 30 mg m^−2^ on days 1 and 8 every 3 weeks, for six cycles. The primary end point was quality of life. Recruitment started in April 1996, and overall 191 patients were randomised.

The MILES study (Multicentre Italian Lung cancer in the Elderly Study ([Gridelli *et al*, 2003b](#bib7){ref-type="other"})) was conducted in the same subset of patients of the ELVIS trial, and compared the combination of vinorelbine and gemcitabine *vs* the two single drugs. Patients were randomly assigned vinorelbine (30 mg m^−2^), gemcitabine (1200 mg m^−2^) or vinorelbine (25 mg m^−2^) plus gemcitabine (1000 mg m^−2^). All treatments were delivered on days 1 and 8 every 3 weeks for six cycles. The primary end point was overall survival. In all, 707 patients were randomised between December 1997 and November 2000.

The GEMVIN3 study ([Gridelli *et al*, 2003a](#bib6){ref-type="other"}) was conducted with adult (\<70 years) patients, randomly assigned vinorelbine (25 mg m^−2^, days 1 and 8) plus gemcitabine (1000 mg m^−2^, days 1 and 8) or cisplatin-based chemotherapy: cisplatin (80 mg m^−2^, day 1) either plus gemcitabine (1200 mg m^−2^, days 1 and 8) or plus vinorelbine (30 mg m^−2^, days 1 and 8) for six cycles of 21 days. The study aimed to assess whether the combination of gemcitabine and vinorelbine improved quality of life, without shortening survival, compared to standard platinum-containing regimens. Accrual started in Italy in October 1998, and in Canada in May 1999. Overall, 503 patients (414 in Italy) were randomised, between October 1998 and March 2001. In this analysis, only Italian patients are considered.

Protocol requirements and data collection on SC
-----------------------------------------------

In all the three trials, investigators were free to choose SC. Each protocol reported only general guidelines about the modalities of administration of the main categories of supportive drugs.

The three-step WHO ladder ([World Health Organization, 1996](#bib17){ref-type="other"}) was recommended for treatment of pain. In case of febrile infections, the association of a third-generation cephalosporin and an aminoglycoside was recommended, with modifications determined by the results of haemoculture. In case of grade 4 neutropenia, prophylactic administration of a quinolone was recommended and use of colony-stimulating factors (CSF) was allowed until resolution of toxicity. No prophylactic administration of CSF was mandated by protocol. Corticosteroids were recommended for hypercalcaemia, respiratory failure and intracranial hypertension.

The three studies had the same Case Report Form for SC. Data were collected from the starting date of chemotherapy until interruption, for up to seven drugs in each cycle of chemotherapy (corresponding to a theoretic 21-day period), with the daily dose and the number of days of assumption recorded. Importantly, drugs administered as premedication before chemotherapy (e.g. antiemetics, diuretics) did not have to be reported in the SC CRF.

All drugs assumed by patients have been coded according to the anatomical therapeutic chemical (ATC) classification system ([World Health Organization Collaborating Centre for Drug Statistics Methodology, 2002](#bib18){ref-type="other"}). This system has been recommended for international studies on drug consumption by the WHO Collaborating Centre for Drug Statistics Methodology. In the ATC system, the drugs are divided into different groups according to the system on which they act and their chemical, pharmacological and therapeutic properties. Drugs are classified at five different levels: 14 main groups (first level), two therapeutic/pharmacological subgroups (second and third levels), a therapeutic/pharmacological/chemical subgroup (fourth level) and the chemical substance (fifth level).

Analysis
--------

In all the three studies analysed, instrumental restaging of the patients was planned after three cycles of chemotherapy, and patients with progressive disease did not receive any more protocol treatment. So, in order to reduce the amount of missing data and possible selection biases, analyses have been limited to the period of time corresponding to the first three cycles (theoretically 63 days). The number of drugs assumed by each patient and frequencies within ATC categories were used for analyses. The whole sample was taken into account for description of the SC pattern. No analysis was carried out on dose and frequency of drug assumption.

For comparative purposes, supportive drugs were grouped into three categories, to reduce the number of statistical comparisons: Drugs used against side effects of treatment: stomatologicals, antiacids, antispasmodics, antiemetics, laxatives, antidiarrhoeals, antihaemorragics, antianaemics, anti-infectives, CSF.Drugs used against tumour-related symptoms: anabolic agents, appetite stimulants, antithrombotics, ACTH and corticosteroids, progestogens, anti-inflammatory drugs and analgesics, drugs affecting demineralisation, antiepileptics, antiasthmatics, expettorants and cough suppressants.Drugs assumed against concomitant diseases: antidiabetics, drugs for cardiovascular system, drugs for thyroid, drugs for benign prostatic hypertrophy, psycholeptics and psychoanaleptics.

This grouping procedure was somewhat arbitrary for some categories (e.g. respiratory drugs could have been prescribed because of concomitant chronic obstructive pulmonary disease rather than tumour symptoms). Vitamins, integrators and mineral supplements, which are not reasonably attributable to any category, were described but not considered in statistical comparisons.

Four questions were addressed in four different subgroups of patients: Does chemotherapy affect SC? -- addressed in patients randomised in the ELVIS trial (vinorelbine *vs* SC) ([The ELVIS group, 1999](#bib16){ref-type="other"}).Does cisplatin-based chemotherapy affect SC? -- addressed in patients randomised in the GEMVIN3 study (cisplatin-based *vs* noncisplatin-based chemotherapy) ([Gridelli *et al*, 2003a](#bib6){ref-type="other"}).Does performance status affect SC? -- addressed comparing patients with PS 0/1 *vs* patients with PS 2 from all the three studies ([The ELVIS group, 1999](#bib16){ref-type="other"}; [Gridelli *et al*, 2003a](#bib6){ref-type="other"}, [2003b](#bib7){ref-type="other"}). Owing to the worse prognosis of PS2 patients and the corresponding reduced number of cycles of chemotherapy, we limited this analysis only to patients who had fulfilled all the three first cycles, in the attempt of not underestimating the assumption of supportive drugs among PS 2 subjects.Does age affect SC? -- addressed comparing patients receiving gemcitabine plus vinorelbine in the GEMVIN3 study ([Gridelli *et al*, 2003a](#bib6){ref-type="other"}) (adults) *vs* those receiving the same chemotherapy in the MILES study ([Gridelli *et al*, 2003b](#bib7){ref-type="other"}) (elderly).

Within randomised comparisons (questions 1 and 2), differences in the number of assumed drugs were tested by the Wilcoxon rank-sum test and differences in the use of different groups of drugs were tested by *χ*^2^ test. Two-sided *P*-values less than 0.05 were considered statistically significant. Questions 3 and 4 used patients from different studies, thus some adjustment was needed. A possible confounding effect, indeed, could arise from enrollment bias among studies when assessing the role of PS and from a different distribution of PS between adult and elderly subjects when assessing the role of age. Thus, stratified Wilcoxon rank-sum test and Mantel--Haenszel test ([Mantel and Haenszel, 1959](#bib10){ref-type="other"}) were carried out after stratification by treatment arm and PS category, respectively (StatXact^©^ turbo, CYTEL software Corp. Cambridge, MA, USA, 1992). Homogeneity assumption among strata was previously tested by the Breslow--Day test ([Breslow and Day, 1980](#bib4){ref-type="other"}).

RESULTS
=======

Data on SC were available in 165 out of 191 patients (86%) in the ELVIS study, in 655 out of 707 (93%) in the MILES study and in 365 out of 414 (88%) in the GEMVIN3 study. Overall, data were available for 1185 patients out of the 1312 (90%) enrolled. Principal characteristics of the 1185 analysed patients, according to treatment arm, are described in [Table 1](#tbl1){ref-type="table"}Table 1Characteristics of the patients for whom information on supportive care (SC) was available, divided by trial and chemotherapy arm**StudyELVIS trialMILES trialGEMVIN3 trial** **ArmSC aloneVinorelbineVinorelbineGemcitabineVinorelbine+gemcitabineVinorelbine+gemcitabineCDDP-based chemotherapyAll patients**Median age (range)74 (69--85)74 (69--85)73 (64--83)73 (69--86)73 (69--84)63 (37--70)64 (36--71)71 (36--86)Gender         Male80 (89%)65 (87%)192 (87%)179 (83%)173 (79%)150 (82%)153 (85%)992 (84%) Female10 (11%)10 (13%)28 (13%)37 (17%)46 (21%)34 (18%)28 (15%)193 (16%)PS         017 (19%)15 (20%)66 (30%)64 (30%)60 (27%)56 (30%)55 (30%)333 (28%) 152 (58%)41 (55%)113 (51%)113 (52%)120 (55%)103 (56%)102 (56%)644 (54%) 221 (23%)19 (25%)41 (19%)39 (18%)39 (18%)25 (14%)24 (13%)208 (18%)         No of patients90752202162191841811185. The median age was 74 years (range 69--85) in the ELVIS study, 73 years (64--86) in the MILES study and 63 years (36--71) in the GEMVIN3 study. Most of the patients were males (88, 83 and 83%, in the ELVIS, MILES and GEMVIN3 trial, respectively). Performance status was equal to 0 in 19, 29 and 30%, equal to 1 in 56, 53 and 56%, and equal to 2 in 24, 18 and 13%, in ELVIS, MILES and GEMVIN3, respectively.

Description of SC
-----------------

A total of 382 different products (corresponding to 265 different active principles), representing 13 of the 14 ATC main groups, were assumed: 136 mainly directed against treatment side effects (95 active principles), 137 against tumour symptoms (88 active principles) and 109 against concomitant diseases (82 active principles). In addition, 21 products were vitamins, integrators and mineral supplements.

Polypharmacotherapy was frequent: patients assumed 2.43 drugs on average; 898 (75.8%) assumed at least one supportive drug, 709 (59.8%) two or more, 538 (45.4%) three or more. The number of drugs assumed was similar across different treatment arms ([Figure 1](#fig1){ref-type="fig"}Figure 1Number of active principles assumed in different treatment arms. Thiner and thicker line in the box: median and mean. Box hinges: 25--75th percentiles; ends of the segments: 10--90th percentiles; dots: 5--95th percentiles. SC=supportive care; Vin=vinorelbine; Gem=gemcitabine; P=cisplatin.).

The number of patients for the main ATC categories and some subcategories are reported in [Table 2](#tbl2){ref-type="table"}Table 2Drugs assumed by the 1185 patients, classified according to the WHO ATC system**ATC codeDescriptionCategoryNo. of pts.(%)**A*Alimentary tract and metabolism* *542(45.7)* A01StomatologicalsSE9(0.8) A02Antacids and drugs for treatment of peptic ulcerSE245(20.7) A03Antispasmodic, anticholinergics and propulsivesSE148(12.5) A04Antiemetics and antinauseantsSE193(16.3) A06LaxativesSE116(9.8) A07Antidiarrhoeals and intestinal anti-infective agentsSE31(2.6) A10Drugs used in diabetesCD18(1.5) A11Vitamins--71(6) A12Mineral supplements--4(0.3) A14Anabolic agents for systemic useTS12(1) A15Appetite stimulantsTS1(0.1) B*Blood and blood-forming organs* *150(12.7)* B01Antithrombotic agentsTS35(3) B02AntihaemorrhagicsSE43(3.6) B03Antianaemic preparationsSE54(4.6) C*Cardiovascular systemCD141(11.9)* D*Dermatologicals*CD3(0.3) G*Genitourinary system and sex hormones* 4(0.3) G04Drugs for benign prostatic hypertrophyCD4(0.3) H*Systemic hormonal preparations* *420(35.4)* H01AAACTHTS39(3.3) H02Corticosteroids for systemic useTS396(33.4) H03Thyroid therapyCD3(0.2) J*General anti-infectives for systemic use* *126(10.6)* J01Antibacterials for systemic useSE114(9.6) J02Antimycotics for systemic useSE20(1.7) L*Antineoplastic and immunomodulating agents* *113(9.5)* L02ABProgestogensTS18(1.5) L03AAColony-stimulating factorsSE97(8.2) M*Muscoloskeletal agents* *222(18.7)* M01ANonsteroidal anti-inflammatory drugsTS200(16.9) M05BDrugs affecting mineralisationTS34(2.9) N*Nervous system (inch. Analgesics)* *282(23.8)* N02AOpioidsTS117(9.9) N02BOther analgesics and antipyreticsTS143(12.1) N03AntiepilepticsTS6(0.5) N05PsycolepticsCD36(3) N06PsycoanalepticsCD15(1.3) N07CAntivertigo preparationsCD2(0.2) P*Antiparasitic productsCD0*-- R*Respiratory system* *195(16.5)* R03AntiasthmaticsTS95(8) R05CExpettorantsTS47(4) R05DCough suppressantsTS90(7.6) S*Sensory organsCD3(0.3)* V*Various*--*23(1.9)*[^1]. Gastrointestinal drugs (A, 45.7%), corticosteroids (H02, 33.4%), analgesics (N, 23.8%), anti-inflammatory drugs (M, 18.7%) and drugs for respiratory system (R, 16.5%) were the most frequently observed ATC codes.

Overall, 680 (57.4%), 633 (53.4%) and 199 (16.8%) patients assumed at least one drug against tumour symptoms, treatment side effects and concomitant diseases, respectively.

Does chemotherapy affect SC?
----------------------------

In the ELVIS study, comparing vinorelbine *vs* SC alone ([Table 3](#tbl3){ref-type="table"}Table 3Does chemotherapy affect supportive care (SC)? **SC alone (*n*=90)Vinorelbine (*n*=75)*P*^a^***Drugs against treatment side effects41 (46%)35 (47%)0.89* A01 Stomatologicals00  A02 Antacids29 (32%)14 (19%)  A03 Antispasmodics4 (4%)5 (7%)  A04 Antiemetics02 (3%)  A06 Laxatives4 (4%)6 (8%)  A07 Antidiarrhoeals1 (1%)1 (1%)  B02 Antihaemorrhagics4 (4%)7 (9%)  B03 Antianaemics1 (1%)3 (4%)  J01 Antibacterials for systemic use10 (11%)6 (8%)  J02 Antimycotics for systemic use01 (1%)  L03AA Colony-stimulating factors05 (7%)  *Drugs against tumour symptoms66 (73%)53 (71%)0.70* A14 Anabolic agents for systemic use3 (3%)3 (4%)  A15 Appetite stimulants1 (1%)0  B01 Antithrombotic agents01 (1%)  H01AA ACTH7 (8%)0  H02 Corticosteroids for systemic use45 (50%)32 (43%)  L02AB Progestogens2 (2%)3 (4%)  M01A Nonsteroidal anti-inflammatory drugs26 (29%)14 (19%)  M05B Drugs affecting mineralisation5 (6%)1 (1%)  N02A Opioids16 (18%)9 (12%)  N02B Other analgesics and antipyretics12 (13%)8 (11%)  N03 Antiepileptics00  R03 Antiasthmatics8 (9%)5 (7%)  R05C Expettorants10 (11%)9 (12%)  R05D Cough suppressants14 (16%)11 (15%)  *Drugs against concomitant diseases27 (30%)17 (23%)0.29* A10 Antidiabetics1 (1%)0  C Cardiovascular system17 (19%)12 (16%)  G04 Drugs for prostatic hypertrophy1 (1%)0  H03 Drugs for thyroid00  N05 Psycholeptics8 (9%)5 (7%)  N06 Psychoanaleptics2 (2%)0  N07C Antivertigo preparations1 (1%)0 [^2][^3]), 131 out of 165 patients (79%) assumed at least one supportive drug. The mean number of supportive drugs assumed in the vinorelbine arm was 2.5 as compared with 2.8 in the SC alone arm (*P*=0.22). Drugs against side effects of treatment were assumed by 46% of patients in SC arm and 47% of those in the vinorelbine arm (*P*=0.89); this result is largely driven by antiacids presumably prescribed to counteract gastric toxicity of corticosteroids and other anti-inflammatory drugs. Drugs against symptoms were assumed by 73% in the SC arm and 71% in the vinorelbine arm (*P*=0.70); drugs against concomitant diseases were assumed by 30% in the SC arm and 23% in the vinorelbine arm (*P*=0.29). As expected, haemopoietic growth factors were assumed only in the chemotherapy arm, by 7% of patients.

Does cisplatin-based chemotherapy affect SC?
--------------------------------------------

In the GEMVIN3 study, comparing cisplatin-based chemotherapy with gemcitabine plus vinorelbine, 288 out of 365 patients (79%) assumed at least one supportive drug. The mean number of supportive drugs was higher in the cisplatin arm (2.6 *vs* 2.2, *P*=0.055). Drugs against treatment side effects were assumed by 66 and 61% of the patients (*P*=0.33), drugs against symptoms by 57 and 53% (*P*=0.42) and drugs against concomitant disease by 11 and 7% (*P*=0.13), in the cisplatin and in the non-cisplatin arm, respectively. As expected, relevant differences were observed for antiemetics (41 *vs* 27%) and antianaemics (10 *vs* 4%), both more frequent in the cisplatin arm ([Table 4](#tbl4){ref-type="table"}Table 4Does cisplatin-based chemotherapy affect SC? **Cisplatin-based (*N*=181)Non-cisplatin (*N*=184)*P*^a^***Drugs against treatment side effects120 (66%)113 (61%)0.33* A01 Stomatologicals00  A02 Antacids39 (22%)39 (21%)  A03 Antispasmodics28 (15%)31 (17%)  A04 Antiemetics75 (41%)49 (27%)  A06 Laxatives14 (8%)18 (10%)  A07 Antidiarrhoeals9 (5%)6 (3%)  B02 Antihaemorrhagics2 (1%)10 (5%)  B03 Antianaemics19 (10%)8 (4%)  J01 Antibacterials for systemic use15 (8%)18 (10%)  J02 Antimycotics for systemic use4 (2%)4 (2%)  L03AA Colony-stimulating factors23 (13%)19 (10%)  *Drugs against tumour symptoms104 (57%)98 (53%)0.42* A14 Anabolic agents for systemic use2 (1%)2 (1%)  A15 Appetite stimulants00  B01 Antithrombotic agents7 (4%)3 (2%)  H01AA ACTH2 (1%)3 (2%)  H02 Corticosteroids for systemic use70 (39%)61 (33%)  L02AB Progestogens3 (2%)0  M01A Nonsteroidal anti-inflammatory drugs38 (21%)26 (14%)  M05B Drugs affecting mineralisation8 (4%)5 (3%)  N02A Opioids19 (10%)10 (5%)  N02B Other analgesics and antipyretics18 (10%)21 (11%)  N03 Antiepileptics02 (1%)  R03 Antiasthmatics9 (5%)15 (8%)  R05C Expettorants4 (2%)3 (2%)  R05D Cough suppressants9 (5%)11 (6%)  *Drugs against concomitant diseases20 (11%)12 (7%)0.13* A10 Antidiabetics4 (2%)1 (1%)  C Cardiovascular system16 (9%)5 (3%)  G04 Drugs for prostatic hypertrophy01 (1%)  H03 Drugs for thyroid01 (1%)  N05 Psycholeptics2 (1%)2 (1%)  N06 Psychoanaleptics1 (2%)2 (1%)  N07C Antivertigo preparations00 [^4][^5]).

Does PS affect SC?
------------------

In the whole series of 1185 patients, 77% of PS 0 and 78% of PS 1 patients received three or more cycles of chemotherapy, as compared to 60% of those with PS 2. This striking difference, possibly due to worse prognosis or reduced tolerance to chemotherapy, leads to underestimation of the amount of supportive drugs consumed by PS 2 patients because of the shorter exposure time. Thus, analysis of the effect of PS on SC was limited to the 883 patients (759 with PS 0--1 and 124 with PS 2) who had fulfilled all the three first cycles: the analysis is still conservative because of the exclusion of the worst performing patients, more frequent among those with PS 2.

Overall, 666 out of 883 patients (75%) assumed at least one supportive drug. The mean number of supportive drugs assumed by PS 0--1 patients was 2.3 as compared with 2.5 in the PS 2 patients (*P*=0.41). Drugs against side effects of treatment were assumed by 53 *vs* 58% (*P*=0.24), drugs against symptoms by 56 *vs* 62% (*P*=0.28), drugs against concomitant diseases by 15 and 23% (*P*=0.10), in patients with better and worse PS, respectively. Patients with worse PS received antiacids and corticosteroids much more frequently than PS 0--1 patients ([Table 5](#tbl5){ref-type="table"}Table 5Does performance status (PS) affect SC? **PS 0/1 (*N*=759)PS 2 (*N*=124)*P*^a^***Drugs against treatment side effects406 (53%)72 (58%)0.24* A01 Stomatologicals8 (1%)1 (1%)  A02 Antacids141 (19%)33 (27%)  A03 Antispasmodics99 (13%)11 (9%)  A04 Antiemetics141 (19%)17 (14%)  A06 Laxatives73 (10%)17 (14%)  A07 Antidiarrhoeals20 (3%)2 (2%)  B02 Antihaemorrhagics27 (4%)5 (4%)  B03 Antianaemics41 (5%)5 (4%)  J01 Antibacterials for systemic use68 (9%)8 (6%)  J02 Antimycotics for systemic use13 (2%)2 (2%)  L03AA Colony-stimulating factors71 (9%)7 (6%)  *Drugs against tumour symptoms424 (56%)77 (62%)0.28* A14 Anabolic agents for systemic use8 (1%)0  A15 Appetite stimulants1 (\<1%)0  B01 Antithrombotic agents28 (4%)0  H01AA ACTH26 (3%)7 (6%)  H02 Corticosteroids for systemic use230 (30%)52 (42%)  L02AB Progestogens11 (1%)1 (1%)  M01A Nonsteroidal anti-inflammatory drugs122 (16%)24 (19%)  M05B Drugs affecting mineralisation18 (2%)4 (3%)  N02A Opioids64 (8%)13 (10%)  N02B Other analgesics and antipyretics97 (13%)20 (16%)  N03 Antiepileptics4 (1%)0  R03 Antiasthmatics61 (8%)9 (7%)  R05C Expettorants27 (4%)5 (4%)  R05D Cough suppressants58 (8%)14 (11%)  *Drugs against concomitant diseases116 (15%)28 (23%)0.10* A10 Antidiabetics12 (2%)0  C Cardiovascular system80 (11%)20 (16%)  G04 Drugs for prostatic hypertrophy2 (\<1%)0  H03 Drugs for thyroid2 (\<1%)1 (1%)  N05 Psycholeptics22 (3%)5 (4%)  N06 Psychoanaleptics9 (1%)2 (2%)  N07C Antivertigo preparations2 (\<1%)0 [^6][^7]).

Does age affect SC?
-------------------

In order to avoid bias related to different chemotherapy, impact of age on SC was studied by comparing 184 adult (\<70 years) *vs* 219 elderly (⩾70 years) patients treated with the same chemotherapy (gemcitabine plus vinorelbine in the MILES and GEMVIN3 studies). Overall, 306 out of 403 patients (76%) received at least one supportive drug. The mean number of supportive drugs assumed by adult patients was 2.2, and that in the elderly patients 2.3 (*P*=0.75). As shown in [Table 6](#tbl6){ref-type="table"}Table 6Does age affect SC? **Adult patients (*N*=184)Elderly patients (*N*=219)*P*^a^***Drugs against treatment side effects113 (61%)120 (55%)0.22* A01 Stomatologicals04 (2%)  A02 Antacids39 (21%)41 (19%)  A03 Antispasmodics31 (17%)27 (12%)  A04 Antiemetics49 (27%)26 (12%)  A06 Laxatives18 (10%)29 (13%)  A07 Antidiarrhoeals6 (3%)7 (3%)  B02 Antihaemorrhagics10 (5%)7 (3%)  B03 Antianaemics8 (4%)12 (5%)  J01 Antibacterials for systemic use18 (10%)21 (10%)  J02 Antimycotics for systemic use4 (2%)3 (1%)  L03AA Colony-stimulating factors19 (10%)22 (10%)  *Drugs against tumour symptoms98 (53%)113 (52%)0.76* A14 Anabolic agents for systemic use2 (1%)0  A15 Appetite stimulants00  B01 Antithrombotic agents3 (2%)8 (4%)  H01AA ACTH3 (2%)14 (6%)  H02 Corticosteroids for systemic use61 (33%)60 (27%)  L02AB Progestogens03 (1%)  M01 A Nonsteroidal anti-inflammatory drugs26 (14%)28 (13%)  M05B Drugs affecting mineralisation5 (3%)5 (2%)  N02A Opioids10 (5%)20 (9%)  N02B Other analgesics and antipyretics21(11%)26 (12%)  N03 Antiepileptics2 (1%)1 (\<1%)  R03 Antiasthmatics15 (8%)15 (7%)  R05C Expettorants3 (2%)3 (1%)  R05D Cough suppressants11 (6%)16 (7%)  *Drugs against concomitant diseases12 (7%)44 (20%)0.0001* A10 Antidiabetics1 (1%)1 (\<1%)  C Cardiovascular system5 (3%)35 (16%)  G04 Drugs for benign prostatic hypertrophy1 (1%)1 (\<1%)  H03 Drugs for thyroid1 (1%)1 (\<1%)  N05 Psycholeptics2 (1%)6 (3%)  N06 Psychoanaleptics2 (1%)2 (1%)  N07C Antivertigo preparations01 (\<1%) [^8][^9], drugs against treatment side effects were assumed by 61 *vs* 55% (*P*=0.22), drugs against symptoms by 53 *vs* 52% (*P*=0.76), drugs against concomitant diseases by 7 *vs* 20% (*P*\<0.0001), in adults and elderly patients, respectively. Among drugs against toxicity, use of antiemetics was more frequent among adults than elderly people (27 *vs* 12%). Among drugs for concomitant diseases, cardiovascular drugs were more frequently used in elderly than adults (16 *vs* 3%).

DISCUSSION
==========

A significant proportion of the patients included in the present analysis assumed three or more different drugs in addition to chemotherapy. Polypharmacotherapy, defined as the simultaneous assumption of many drugs, can produce noxious effects ([Alderman, 2000](#bib1){ref-type="other"}). Among the several problems related to polypharmacotherapy, one of the most frequently addressed is the higher number of adverse drug reactions and drug--drug interactions, which can become crucial with drugs with a narrow therapeutic index, that is, small difference between therapeutic and toxic doses. Another problem is treatment compliance; the more drugs a patient takes, the harder it is to keep their administration correct. For example, in a study of patients with either diabetes or congestive heart failure, among patients taking one drug, 15% made errors, while those taking two or three drugs had a 25% error rate and over 35% of those taking four or more drugs made errors ([Hulka *et al*, 1975](#bib8){ref-type="other"}). In a large study analysing the causes of medical emergencies in elderly people ([Malhotra *et al*, 2001](#bib9){ref-type="other"}), there was a significant contribution of adverse drug reactions, accounting for 6.7% of the events, and noncompliance with medications, accounting for another 7.6%. Polypharmacotherapy was associated with an increased risk of admission both for adverse reactions and noncompliance. Last but not least, pharmacoeconomic considerations should not be forgotten, especially when prescribing drugs characterised by high costs.

We divided supportive drugs into three categories: drugs against treatment side effects, against tumour symptoms and against concomitant diseases. More than half of the patients assumed drugs of the first two groups, while one-fifth assumed drugs against concomitant diseases. Our classification could be debatable for some drugs that can be prescribed with different purposes, for example, antibiotics in the SC arm of the ELVIS trial (see [Table 3](#tbl3){ref-type="table"}) that were probably prescribed to counteract infectious episodes typical of chronic obstructive pulmonary disease frequently associated with lung cancer.

Studying factors affecting the use of supportive drugs we found four main results: (i) a relatively low-toxic chemotherapeutic agent (vinorelbine) does not produce substantial variations in the SC pattern; (ii) a more toxic cisplatin-based treatment requires an overall higher number of supportive drugs, and exposes a higher rate of patients to antiemetics and antianaemics; (iii) a deteriorated performance status is associated with an increased exposure to corticosteroids and a general tendency to an increased use of supportive drugs; (iv) elderly patients require drugs against concomitant diseases significantly more than adults and are less exposed to antiemetics.

As for the first two points, it is a common opinion that side effects of chemotherapy impair quality of life and require assumption of drugs against toxicity. Impact of chemotherapy on quality of life was ruled out by the primary analysis of the ELVIS study showing an overall improvement of quality of life ([The ELVIS group, 1999](#bib16){ref-type="other"}), and it appears now that there are no statistically significant differences in the SC pattern, with the obvious exception on CSFs, not used in the SC arm. The similar rate of patients exposed to antiacid in the two arms is clearly related to the prevention of gastric side effects of corticosteroids, assumed by about half of the patients. Of course, this result is driven by the use of single agent vinorelbine, a drug known for its good tolerability and the relatively low incidence of side effects. In fact, a difference in the mean number of drugs assumed by the patients was found between the arm receiving cisplatin-based chemotherapy and the arm receiving chemotherapy without cisplatin, in the GEMVIN3 trial. The higher incidence of side effects following cisplatin administration (e.g. nausea/vomiting among nonhaematologic toxicities, anaemia among haematologic toxicities) produced higher assumption of several drug categories (e.g. antiemetics and antianaemic preparations) when compared to the combination of two less toxic drugs, gemcitabine and vinorelbine.

Performance status has an important prognostic role in patients with advanced NSCLC ([Ando *et al*, 2001](#bib2){ref-type="other"}). A worse PS can be related to pre-existing comorbid conditions, or to pain and other cancer symptoms. Although not reaching a statistically significant difference in the mean number of drugs assumed, a higher intake by patients with worse PS was observed for several drugs against concomitant diseases and cancer symptoms, particularly for corticosteroids. However, our conservative strategy of comparing only patients who actually received three cycles does probably decrease the differences, excluding patients with worse health status among those with PS 2.

As for the impact of age on SC, the higher assumption of drugs for cardiovascular system among elderly patients reflects the higher frequency of comorbidities among these patients ([Repetto and Balducci, 2002](#bib14){ref-type="other"}). The finding that antiemetic agents are more frequently used in younger than older patients, during the same chemotherapy, was unexpected. It is not fully justifiable with incidence of vomiting in the two studies: overall 38% of elderly and 46% of adult patients suffered any grade vomiting, with 8 *vs* 11% suffering grade 2, respectively, and only 1% grade 3 in both groups. With the exception of the higher incidence of acute dystonic reactions in younger patients, age should not significantly predict the incidence of chemotherapy-induced nausea and vomiting or the response to antiemetic treatment. Some studies have shown better control in older patients, whereas others have reported little difference among age groups ([Berger and Clark-Snow, 1997](#bib3){ref-type="other"}). Part of the large difference observed may probably be explained with reluctance in prescribing antiemetics to elderly patients, for whom these drugs could be less manageable and with higher incidence of toxicity.

As this is a secondary analysis of three prospective trials pooled together, some consideration need to be given on the quality of the evidences found. The first two questions (the impact of chemotherapy *vs* SC alone and the impact of cisplatin-based chemotherapy) were each addressed within a specific randomised study; in both of these studies, data on SC were available for most of the patients. Of course, although an *a priori* hypotheses had not been stated and no power calculation had been carried out as for the questions raised in this paper, statistical comparisons presented here can be considered correct, thanks to the randomised design. The two questions regarding the impact of patients\' PS and age have been addressed across different randomised studies; thus, they represent indirect explorative subgroup comparisons and their results should be treated with caution. Notwithstanding these limitations, evidences presented here are among the strongest available in the literature. Indeed, descriptions of SC patterns in association with chemotherapy practically do not exist, to the best of our knowledge; in addition, while much interest has been paid to specific drug classes (e.g. antiemetics, CSFs and antibiotics), less attention has been paid to polypharmacotherapy, and to the degree of cytotoxic chemotherapy, and patients\' characteristics do affect the overall burden of SC. This is disturbing, considering that oncologists continuously face empiric integration of antineoplastic and supportive drugs. Further studies aimed at a 'wide-angle' treatment approach are awaited, which could probably improve our ability of correctly managing cancer patients.

As a final consideration, we believe that three major messages come from our findings: (i) more attention should be paid in clinical practice and research to drug interactions, frequently not well studied and potentially dangerous; (ii) choosing different cytotoxic drugs translates into different levels of cost and drug interaction risk in SC patterns; these consequences should be considered in treatment choice both at singular and population levels; (iii) there are subgroups of patients for whom the issue of SC looks of paramount importance not only because of the limited efficacy of antineoplastic drugs but also for the higher risk of drug interactions. Nevertheless, SC is usually neglected as a matter of research, even in these high-risk patient subgroups.
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[^1]: SE=against side effects of treatment; TS=against tumour symptoms; CD=against concomitant diseases.

[^2]: Elderly patients randomised in the ELVIS trial. The table shows the number (percentage) of patients assuming at least one drug of each category during the first 63 days of treatment.

[^3]: *χ*^2^ test.

[^4]: Adult Italian patients randomized in the GEMVIN3 study. The table shows the number (percentage) of patients assuming at least one drug of each category during the first 63 days of treatment

[^5]: *χ*^2^ test.

[^6]: Patients with PS 0/1 *vs* patients with PS 2 in all three studies. The table shows the number (percentage) of patients assuming at least one drug of each category during the first 63 days of treatment. Only patients receiving three or more cycles of chemotherapy are considered.

[^7]: Mantel Haenszel test stratified by treatment arm.

[^8]: Patients receiving gemcitabine plus vinorelbine in the GEMVIN3 study (adult patients) *vs* those receiving the same chemotherapy in the MILES study (elderly patients). The table shows the number (percentage) of patients assuming at least one drug of each category during the first 63 days of treatment.

[^9]: Mantel--Haenszel test stratified by PS category.
